Sophiris Bio Inc T.SHS

Primary Symbol: SPHS

Healthcare Biotechnology

Sophiris Bio Inc is a clinical-stage biopharmaceutical company. It focuses on the development of products for the treatment of urological diseases. The company's product portfolio includes topsalysin (PRX302), for the treatment of lower urinary tract symptoms of benign prostatic hyperplasia (BPH), as well as for the treatment of localized low to intermediate risk prostate cancer. Topsalysin is a genetically modified recombinant protein which is selectively activated by enzymatically active prostate-specific antigen (PSA), which is only present in the prostate, leading to localized cell death and tissue disruption without damage to neighboring tissue and nerves. Geographically all the operations of the company are functioned in the United States.

EXPM:SPHS - Post by User

Sophiris Bio Inc

Bullboard Posts

Comment by rythmanon Nov 08, 2013 12:38pm

151 Views

Post# 21889076

RE:RE:RE:FDA approves Medivation prostate cancer drug

Right I agree, and it only costs about $7,000 a month for a prescription. Not really a SHS/SPHS deal killer.
For those concerned about the TSX listing, the symbol on Q is SPHS. It trades about 60,000 shares
a day on average. You will end up with the same number of shares only in US dollars.
I sold my non-registered shares for a capital loss, am considering buying SPHS in new year. Still, we have over a year before results are available.
rythman

Bullboard Posts

BMO launches enhanced platform with tools for options trading